Ferring Pharmaceuticals announces optimisation of operations to accelerate growth
in STATEMENT 2025 on
Read more0
0
-
-
Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec
in PRESS RELEASE 2025 onRead more…
-
Ferring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate growth and innovation
in STATEMENT 2025 onRead moreFerring announces new Ambition, Enterprise Model and Executive Committee composition to accelerate…
-
Bladder Cancer Awareness Month 2025: Ferring partners with the community to strengthen its commitment to improve patient outcomes
in NEWS onRead moreBladder Cancer Awareness Month 2025: Ferring partners with the community to strengthen…
-
Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients
in PRESS RELEASE 2025 onRead moreFerring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of…
-
U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2025 onRead moreU.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)…
-
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC patients
in PRESS RELEASE 2025 onRead moreFerring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating…
-
Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin
in PRESS RELEASE 2025 onRead moreFerring achieved record sales driven by Reproductive Medicine combined with the emergence…